日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer

犬类癌症患者服用经美国食品药品监督管理局批准的洛莫司汀制剂及复方制剂后发生中性粒细胞减少症的频率和严重程度

Burton, J H; Stanley, S D; Knych, H K; Rodriguez, C O; Skorupski, K A; Rebhun, R B

Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.

脉冲式给药磷酸托西拉尼联合洛莫司汀治疗犬类不可切除的肥大细胞瘤

Burton J H, Venable R O, Vail D M, Williams L E, Clifford C A, Axiak-Bechtel S M, Avery A C, Thamm D H

Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma

比较470只因肢体骨肉瘤截肢后采用卡铂和多柔比星化疗方案的疗效

Selmic, L E; Burton, J H; Thamm, D H; Withrow, S J; Lana, S E

Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma

VDC-1101治疗犬皮肤T细胞淋巴瘤的II期临床试验

Morges, M A; Burton, J H; Saba, C F; Vail, D M; Burgess, K E; Thamm, D H

Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma

CD8+ T细胞与调节性T细胞比例降低与患有骨肉瘤的犬只生存率降低相关

Biller, B J; Guth, A; Burton, J H; Dow, S W